José Andrés Castro-Gamboa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
José Andrés Castro-Gamboa has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Esteban Zavaleta-Monestel
Hospital Pharmacy Section, International Pharmaceutical Federation, The Hague, ZH, The Netherlands
10 shared publications - Jeaustin Mora-Jiménez
Health Research Department, Clínica Bíblica, San José 1307-1000, Costa Rica
10 shared publications - Sebastián Arguedas-Chacón
Health Research Department, Clínica Bíblica, San José 1307-1000, Costa Rica
10 shared publications - Kevin Cruz-Mora
Pharmacy Department, Clínica Bíblica, San José 1307-1000, Costa Rica
7 shared publications - Luis Guillermo Herrera-Jiménez
Department of Pharmacy, University of Costa Rica, San Jose 11501-2060, Costa Rica
6 shared publications - José Miguel Chaverri-Fernández
Department of Pharmacy, University of Costa Rica, San Jose 11501-2060, Costa Rica
4 shared publications
Latest Publications
- Open Access
Pharmaceutical Indication and Pharmacist Prescribing in Primary Care: An International Comparative Characterization of Regulatory Models, Clinical Scope, and Evidence Synthesis
Pharmaceutical indication and pharmacist prescribing are distinct mechanisms through which community pharmacists can contribute to primary care, particularly in managing minor symptoms and low-complexity conditions. This narrative review critically compared scientific, regulatory, and institutional sources identified through PubMed/MEDLINE, ScienceDirect, Google Scholar, and consultation of regulatory and professional documents. Domains of the Scale for the Assessment of Narrative Review Articles (SANRA) informed appraisal of the manuscript, rather than source selection or assessment of individual studies. Four recurrent analytical configurations were identified: pharmaceutical indication, protocol-based medicine supply or prescribing, collaborative prescribing, and independent prescribing. Their legal bases, clinical scopes, medicine-access mechanisms, and implementation requirements differ between and within jurisdictions. In the examples reviewed, structured services variously specify eligibility criteria, red-flag assessment, safety-netting, referral, documentation, and coordination with other healthcare professionals. Heterogeneous study designs and outcome measures limit comparisons of clinical effectiveness, safety, service utilization, and costs; no universal hierarchy among regulatory configurations can be established. In selected Latin American settings, including Costa Rica, pharmaceutical consultation and indication are documented, although formalization varies. Future research should prioritize comparable definitions, standardized outcomes, and sustainability.
Open AccessPharmaceutical Indication and Pharmacist Prescribing in Primary Care: An International Comparative Characterization of Regulatory Models, Clinical Scope, and Evidence Synthesis
Pharmaceutical indication and pharmacist prescribing are distinct mechanisms through which community pharmacists can contribute to primary care, particularly in managing minor symptoms and low-complexity conditions. This narrative review critically compared scientific, regulatory, and institutional sources identified through PubMed/MEDLINE, ScienceDirect, Google Scholar, and consultation of regulatory and professional documents. Domains of the Scale for the Assessment of Narrative Review Articles (SANRA) informed appraisal of the manuscript, rather than source selection or assessment of individual studies. Four recurrent analytical configurations were identified: pharmaceutical indication, protocol-based medicine supply or prescribing, collaborative prescribing, and independent prescribing. Their legal bases, clinical scopes, medicine-access mechanisms, and implementation requirements differ between and within jurisdictions. In the examples reviewed, structured services variously specify eligibility criteria, red-flag assessment, safety-netting, referral, documentation, and coordination with other healthcare professionals. Heterogeneous study designs and outcome measures limit comparisons of clinical effectiveness, safety, service utilization, and costs; no universal hierarchy among regulatory configurations can be established. In selected Latin American settings, including Costa Rica, pharmaceutical consultation and indication are documented, although formalization varies. Future research should prioritize comparable definitions, standardized outcomes, and sustainability.
- Open Access
- 2 November 2026
- Published by MDPI AG in Pharmacoepidemiology
- Vol. 5 (4) , 46
Comparative Cardiac Adverse-Event Reporting Patterns Across Antineoplastic Therapeutic Classes: A Global Analysis Using WHO VigiAccess
Background/Objectives: Cardiac adverse-event reports for antineoplastic agents may differ across regulatory coding categories, affecting disproportionality estimates. We compared anthracyclines, human epidermal growth factor receptor 2 (HER2)-targeted agents, and vascular endothelial growth factor (VEGF) inhibitors. Methods: We analyzed aggregated World Health Organization VigiAccess data retrieved on March 23, 2026, for eight drugs in three classes. Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class and cardiac Preferred Term distributions were described; reporting odds ratios (RORs) with 95% confidence intervals (CIs) were calculated using a restricted antineoplastic comparator cohort. Pairwise within-cohort comparators and cardiac/vascular outcomes were explored; an external database-wide comparison was not feasible. Results: Across 389,068 drug-specific report observations, anti-HER2 agents had the highest proportion classified under Cardiac disorders (10.43%) and the strongest class-level ROR (2.04; 95% CI 1.99–2.10); trastuzumab had the highest drug-level ROR (2.22; 2.16–2.29). Anthracyclines contributed the most cardiac reports (11,273), whereas anti-VEGF agents showed greater proportional reporting in vascular disorders (10.86%) and prominent myocardial infarction reports among cardiac Preferred Terms. Exploratory analyses demonstrated sensitivity to comparator composition and outcome definition. Conclusions: Reporting patterns varied across classes, but these findings do not establish incidence, causality, comparative clinical risk, or independent grounds for changing surveillance protocols.
- 2 November 2026
- Published by MDPI AG in Pharmacoepidemiology
- Vol. 5 (4) , 46
Open AccessComparative Cardiac Adverse-Event Reporting Patterns Across Antineoplastic Therapeutic Classes: A Global Analysis Using WHO VigiAccess
Background/Objectives: Cardiac adverse-event reports for antineoplastic agents may differ across regulatory coding categories, affecting disproportionality estimates. We compared anthracyclines, human epidermal growth factor receptor 2 (HER2)-targeted agents, and vascular endothelial growth factor (VEGF) inhibitors. Methods: We analyzed aggregated World Health Organization VigiAccess data retrieved on March 23, 2026, for eight drugs in three classes. Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class and cardiac Preferred Term distributions were described; reporting odds ratios (RORs) with 95% confidence intervals (CIs) were calculated using a restricted antineoplastic comparator cohort. Pairwise within-cohort comparators and cardiac/vascular outcomes were explored; an external database-wide comparison was not feasible. Results: Across 389,068 drug-specific report observations, anti-HER2 agents had the highest proportion classified under Cardiac disorders (10.43%) and the strongest class-level ROR (2.04; 95% CI 1.99–2.10); trastuzumab had the highest drug-level ROR (2.22; 2.16–2.29). Anthracyclines contributed the most cardiac reports (11,273), whereas anti-VEGF agents showed greater proportional reporting in vascular disorders (10.86%) and prominent myocardial infarction reports among cardiac Preferred Terms. Exploratory analyses demonstrated sensitivity to comparator composition and outcome definition. Conclusions: Reporting patterns varied across classes, but these findings do not establish incidence, causality, comparative clinical risk, or independent grounds for changing surveillance protocols.
- Open Access
- 9 October 2026
- Published by MDPI AG in Preprints.org
Pharmaceutical Indication and Pharmacist Prescribing in Primary Care: An International Comparative Characterization of Regulatory Models, Clinical Scope, and Evidence Synthesis
Pharmaceutical indication and pharmacist prescribing have become strategies for expanding the capacity of primary care, particularly in the management of minor symptoms and low-complexity clinical conditions. This narrative review, guided by the SANRA domains, integrated scientific, regulatory, and institutional evidence identified through PubMed/MEDLINE, ScienceDirect, and Google Scholar, supplemented by grey literature from regulatory bodies, health services, and professional organizations, to comparatively characterize regulatory and practice models described across jurisdictions. Four main configurations were identified: pharmaceutical indication, protocol-based models, collaborative prescribing, and independent prescribing, with heterogeneous implementation internationally. Available evidence reports favorable outcomes in some services, including improved accessibility, high user satisfaction, and a potential shift in consultations from other healthcare settings to community pharmacy; however, heterogeneity in study designs, settings, and outcome measures, together with the predominance of observational and implementation studies, limits the certainty of these findings. Rather than demonstrating the superiority of a particular level of professional autonomy, the literature consistently shows that structured models incorporate clinical protocols, eligibility criteria, red-flag assessment, safety-netting, referral, and documentation. Effective implementation also requires consideration of professional training, care integration, documentation systems, and sustainable funding mechanisms. In Latin America and Costa Rica, the literature documents frequent pharmaceutical consultation and indication practices, although with variable levels of formalization and standardization.
- 9 October 2026
- Published by MDPI AG in Preprints.org
Open AccessPharmaceutical Indication and Pharmacist Prescribing in Primary Care: An International Comparative Characterization of Regulatory Models, Clinical Scope, and Evidence Synthesis
Pharmaceutical indication and pharmacist prescribing have become strategies for expanding the capacity of primary care, particularly in the management of minor symptoms and low-complexity clinical conditions. This narrative review, guided by the SANRA domains, integrated scientific, regulatory, and institutional evidence identified through PubMed/MEDLINE, ScienceDirect, and Google Scholar, supplemented by grey literature from regulatory bodies, health services, and professional organizations, to comparatively characterize regulatory and practice models described across jurisdictions. Four main configurations were identified: pharmaceutical indication, protocol-based models, collaborative prescribing, and independent prescribing, with heterogeneous implementation internationally. Available evidence reports favorable outcomes in some services, including improved accessibility, high user satisfaction, and a potential shift in consultations from other healthcare settings to community pharmacy; however, heterogeneity in study designs, settings, and outcome measures, together with the predominance of observational and implementation studies, limits the certainty of these findings. Rather than demonstrating the superiority of a particular level of professional autonomy, the literature consistently shows that structured models incorporate clinical protocols, eligibility criteria, red-flag assessment, safety-netting, referral, and documentation. Effective implementation also requires consideration of professional training, care integration, documentation systems, and sustainable funding mechanisms. In Latin America and Costa Rica, the literature documents frequent pharmaceutical consultation and indication practices, although with variable levels of formalization and standardization.
- Open Access
- 3 October 2026
- Published by MDPI AG in Psychoactives
- Vol. 5 (4) , 27
Private-Sector Sales Trends of Antidepressants and Antipsychotics in Costa Rica, 2022–2026: An Aggregate Analysis by Active Ingredient
Aggregated pharmaceutical sales data can characterize apparent medication consumption and changes in market composition, although they do not represent individual prescribing or patient exposure. This study described private-sector sales trends of antidepressants and antipsychotics in Costa Rica from moving annual total (MAT) February 2022 to MAT February 2026. An observational, descriptive, longitudinal study was conducted using aggregated IQVIA sales data. Total defined daily doses (DDDs) sold were analyzed as the primary indicator, complemented by units sold and analyses by therapeutic group and active ingredient. Antidepressant DDDs increased from 15,299,281 to 17,976,312 (+17.5%), whereas antipsychotic DDDs increased from 1,078,635 to 1,476,810 (+36.9%). In 2026, escitalopram and sertraline had the highest DDD volumes among antidepressants, while quetiapine was the leading antipsychotic. Desvenlafaxine was the largest contributor to net antidepressant growth, whereas aripiprazole and lurasidone contributed substantially to antipsychotic growth. Overall, private-sector sales of both therapeutic groups increased, with distinct patterns across active ingredients. These findings provide a baseline for pharmaceutical market surveillance but should not be interpreted as estimates of total national consumption, public-sector utilization, individual prescribing, clinical indications, or actual patient exposure.
- 3 October 2026
- Published by MDPI AG in Psychoactives
- Vol. 5 (4) , 27
Open AccessPrivate-Sector Sales Trends of Antidepressants and Antipsychotics in Costa Rica, 2022–2026: An Aggregate Analysis by Active Ingredient
Aggregated pharmaceutical sales data can characterize apparent medication consumption and changes in market composition, although they do not represent individual prescribing or patient exposure. This study described private-sector sales trends of antidepressants and antipsychotics in Costa Rica from moving annual total (MAT) February 2022 to MAT February 2026. An observational, descriptive, longitudinal study was conducted using aggregated IQVIA sales data. Total defined daily doses (DDDs) sold were analyzed as the primary indicator, complemented by units sold and analyses by therapeutic group and active ingredient. Antidepressant DDDs increased from 15,299,281 to 17,976,312 (+17.5%), whereas antipsychotic DDDs increased from 1,078,635 to 1,476,810 (+36.9%). In 2026, escitalopram and sertraline had the highest DDD volumes among antidepressants, while quetiapine was the leading antipsychotic. Desvenlafaxine was the largest contributor to net antidepressant growth, whereas aripiprazole and lurasidone contributed substantially to antipsychotic growth. Overall, private-sector sales of both therapeutic groups increased, with distinct patterns across active ingredients. These findings provide a baseline for pharmaceutical market surveillance but should not be interpreted as estimates of total national consumption, public-sector utilization, individual prescribing, clinical indications, or actual patient exposure.
- Open Access
- 29 September 2026
- Published by MDPI AG in Preprints.org
Comparative Cardiac Adverse-Event Reporting Patterns Across Antineoplastic Therapeutic Classes: A Global Analysis Using WHO VigiAccess
Background/Objectives: Antineoplastic therapies have improved cancer survival but remain a major source of treatment-related cardiotoxicity. Previous pharmacovigilance studies have largely focused on drug-specific cardiac signals or individual therapeutic pathways, whereas cross-class differences in cardiovascular reporting across MedDRA categories and their impact on disproportionality estimates remain less well characterized. We therefore compared cardiac adverse-event reporting patterns across anthracyclines, anti-HER2 agents, and anti-VEGF agents within a restricted antineoplastic comparator cohort. Methods: A retrospective pharmacovigilance study was conducted using aggregated ICSR data from VigiBase accessed through the public VigiAccess interface (March 23, 2026). Eight antineoplastic agents were grouped into three therapeutic classes. Descriptive analyses of demographic characteristics, System Organ Class (SOC) distributions, and cardiac Preferred Terms (PT) were performed. Reporting Odds Ratios (ROR) with 95% confidence intervals were calculated using a restricted antineoplastic comparator cohort. Signals were defined as a lower 95% CI bound >1 with at least five cardiac reports. Results: Across eight drug-specific VigiAccess queries, 389,068 drug-specific report observations were analyzed. Anti-HER2 agents showed the highest proportional cardiac-reporting burden (10.43%) and the strongest class-level disproportionality signal (ROR 2.04; 95% CI: 1.99–2.10), with trastuzumab showing the strongest individual-drug estimate (ROR 2.22; 95% CI: 2.16–2.29). Anthracyclines accounted for the largest number of cardiac reports (n = 11,273), with a reporting pattern dominated by myocardial-dysfunction Preferred Terms, led by cardiomyopathy and heart failure. Anti-VEGF agents showed greater reporting within the Vascular disorders (10.86%) and Renal and urinary disorders (6.08%) SOCs, with myocardial infarction among the most frequently reported cardiac PTs. Conclusions: Cardiac adverse event reporting for antineoplastic therapy follows class-specific patterns rather than a uniform profile. Anti-HER2 agents showed the highest proportion of reports classified under Cardiac disorders, anthracyclines the greatest absolute volume, and anti-VEGF therapies exhibited a distinct vascular–ischemic reporting profile. These reporting-based signals may support hypotheses regarding class-specific cardiovascular surveillance consistent with established cardio-oncology guidance, while highlighting both the value and the inherent limitations of global spontaneous-reporting pharmacovigilance data. These findings are hypothesis-generating and should be interpreted as reporting patterns rather than incidence estimates, comparative clinical risks, or causal effects. Spontaneous-reporting data remain susceptible to reporting bias, unmeasured confounding, and incomplete clinical information.
- 29 September 2026
- Published by MDPI AG in Preprints.org
Open AccessComparative Cardiac Adverse-Event Reporting Patterns Across Antineoplastic Therapeutic Classes: A Global Analysis Using WHO VigiAccess
Background/Objectives: Antineoplastic therapies have improved cancer survival but remain a major source of treatment-related cardiotoxicity. Previous pharmacovigilance studies have largely focused on drug-specific cardiac signals or individual therapeutic pathways, whereas cross-class differences in cardiovascular reporting across MedDRA categories and their impact on disproportionality estimates remain less well characterized. We therefore compared cardiac adverse-event reporting patterns across anthracyclines, anti-HER2 agents, and anti-VEGF agents within a restricted antineoplastic comparator cohort. Methods: A retrospective pharmacovigilance study was conducted using aggregated ICSR data from VigiBase accessed through the public VigiAccess interface (March 23, 2026). Eight antineoplastic agents were grouped into three therapeutic classes. Descriptive analyses of demographic characteristics, System Organ Class (SOC) distributions, and cardiac Preferred Terms (PT) were performed. Reporting Odds Ratios (ROR) with 95% confidence intervals were calculated using a restricted antineoplastic comparator cohort. Signals were defined as a lower 95% CI bound >1 with at least five cardiac reports. Results: Across eight drug-specific VigiAccess queries, 389,068 drug-specific report observations were analyzed. Anti-HER2 agents showed the highest proportional cardiac-reporting burden (10.43%) and the strongest class-level disproportionality signal (ROR 2.04; 95% CI: 1.99–2.10), with trastuzumab showing the strongest individual-drug estimate (ROR 2.22; 95% CI: 2.16–2.29). Anthracyclines accounted for the largest number of cardiac reports (n = 11,273), with a reporting pattern dominated by myocardial-dysfunction Preferred Terms, led by cardiomyopathy and heart failure. Anti-VEGF agents showed greater reporting within the Vascular disorders (10.86%) and Renal and urinary disorders (6.08%) SOCs, with myocardial infarction among the most frequently reported cardiac PTs. Conclusions: Cardiac adverse event reporting for antineoplastic therapy follows class-specific patterns rather than a uniform profile. Anti-HER2 agents showed the highest proportion of reports classified under Cardiac disorders, anthracyclines the greatest absolute volume, and anti-VEGF therapies exhibited a distinct vascular–ischemic reporting profile. These reporting-based signals may support hypotheses regarding class-specific cardiovascular surveillance consistent with established cardio-oncology guidance, while highlighting both the value and the inherent limitations of global spontaneous-reporting pharmacovigilance data. These findings are hypothesis-generating and should be interpreted as reporting patterns rather than incidence estimates, comparative clinical risks, or causal effects. Spontaneous-reporting data remain susceptible to reporting bias, unmeasured confounding, and incomplete clinical information.
- Open Access
- 12 August 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (3) , 54
Contrast Media-Associated Nephrotoxicity: A Narrative Review of Pathophysiology, Risk Factors, Prevention, and Clinical Management
Background: Contrast media are essential tools in diagnostic and interventional imaging, but their relationship with acute kidney injury remains clinically relevant and conceptually debated. This narrative review aimed to synthesize current evidence on contrast media-associated nephrotoxicity, including terminology, epidemiology, pathophysiology, risk stratification, prevention, pharmacotherapeutic management, and clinical decision-making. Methods: A structured literature search was conducted in major biomedical databases and complemented by international guidelines and consensus statements addressing contrast-associated and contrast-induced acute kidney injury in adults exposed to intravascular contrast media. Discussion: Contemporary evidence emphasizes the distinction between contrast-associated acute kidney injury, which reflects a temporal association after exposure, and contrast-induced acute kidney injury, which implies causality. The renal risk directly attributable to modern intravenous iodinated contrast media appears to have been historically overestimated, although clinically relevant risk persists in vulnerable patients. Proposed mechanisms include renal vasoconstriction, medullary hypoxia, oxidative stress, mitochondrial dysfunction, tubular epithelial injury, endothelial dysfunction, and inflammatory or apoptotic pathways. Preventive strategies should be individualized, with isotonic saline remaining the main intervention when indicated, whereas routine pharmacologic prophylaxis is not supported by consistent clinically meaningful benefit. Conclusions: Renal safety in contrast-enhanced imaging requires a balanced approach that minimizes avoidable kidney injury in high-risk patients without unnecessarily delaying clinically indicated diagnostic or therapeutic procedures.
- 12 August 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (3) , 54
Open AccessContrast Media-Associated Nephrotoxicity: A Narrative Review of Pathophysiology, Risk Factors, Prevention, and Clinical Management
Background: Contrast media are essential tools in diagnostic and interventional imaging, but their relationship with acute kidney injury remains clinically relevant and conceptually debated. This narrative review aimed to synthesize current evidence on contrast media-associated nephrotoxicity, including terminology, epidemiology, pathophysiology, risk stratification, prevention, pharmacotherapeutic management, and clinical decision-making. Methods: A structured literature search was conducted in major biomedical databases and complemented by international guidelines and consensus statements addressing contrast-associated and contrast-induced acute kidney injury in adults exposed to intravascular contrast media. Discussion: Contemporary evidence emphasizes the distinction between contrast-associated acute kidney injury, which reflects a temporal association after exposure, and contrast-induced acute kidney injury, which implies causality. The renal risk directly attributable to modern intravenous iodinated contrast media appears to have been historically overestimated, although clinically relevant risk persists in vulnerable patients. Proposed mechanisms include renal vasoconstriction, medullary hypoxia, oxidative stress, mitochondrial dysfunction, tubular epithelial injury, endothelial dysfunction, and inflammatory or apoptotic pathways. Preventive strategies should be individualized, with isotonic saline remaining the main intervention when indicated, whereas routine pharmacologic prophylaxis is not supported by consistent clinically meaningful benefit. Conclusions: Renal safety in contrast-enhanced imaging requires a balanced approach that minimizes avoidable kidney injury in high-risk patients without unnecessarily delaying clinically indicated diagnostic or therapeutic procedures.
- Open Access
- 6 July 2026
- Published by MDPI AG in Preprints.org
Contrast Media-Associated Nephrotoxicity: A Narrative Review of Pathophysiology, Risk Factors, Prevention, and Clinical Management
Background: Contrast media are essential tools in diagnostic and interventional imaging, but their relationship with acute kidney injury remains clinically relevant and conceptu-ally debated. This narrative review aimed to synthesize current evidence on contrast me-dia-associated nephrotoxicity, including terminology, epidemiology, pathophysiology, risk stratification, prevention, pharmacotherapeutic management, and clinical deci-sion-making. Methods: A structured literature search was conducted in major biomedical databases and complemented by international guidelines and consensus statements ad-dressing contrast-associated and contrast-induced acute kidney injury in adults exposed to intravascular contrast media. Discussion: Contemporary evidence emphasizes the dis-tinction between contrast-associated acute kidney injury, which reflects a temporal asso-ciation after exposure, and contrast-induced acute kidney injury, which implies causality. The renal risk directly attributable to modern intravenous iodinated contrast media ap-pears to have been historically overestimated, although clinically relevant risk persists in vulnerable patients. Proposed mechanisms include renal vasoconstriction, medullary hy-poxia, oxidative stress, mitochondrial dysfunction, tubular epithelial injury, endothelial dysfunction, and inflammatory or apoptotic pathways. Preventive strategies should be in-dividualized, with isotonic saline remaining the main intervention when indicated, whereas routine pharmacologic prophylaxis is not supported by consistent clinically meaningful benefit. Conclusions: Renal safety in contrast-enhanced imaging requires a balanced approach that minimizes avoidable kidney injury in high-risk patients without unnecessarily delaying clinically indicated diagnostic or therapeutic procedures.
- 6 July 2026
- Published by MDPI AG in Preprints.org
Open AccessContrast Media-Associated Nephrotoxicity: A Narrative Review of Pathophysiology, Risk Factors, Prevention, and Clinical Management
Background: Contrast media are essential tools in diagnostic and interventional imaging, but their relationship with acute kidney injury remains clinically relevant and conceptu-ally debated. This narrative review aimed to synthesize current evidence on contrast me-dia-associated nephrotoxicity, including terminology, epidemiology, pathophysiology, risk stratification, prevention, pharmacotherapeutic management, and clinical deci-sion-making. Methods: A structured literature search was conducted in major biomedical databases and complemented by international guidelines and consensus statements ad-dressing contrast-associated and contrast-induced acute kidney injury in adults exposed to intravascular contrast media. Discussion: Contemporary evidence emphasizes the dis-tinction between contrast-associated acute kidney injury, which reflects a temporal asso-ciation after exposure, and contrast-induced acute kidney injury, which implies causality. The renal risk directly attributable to modern intravenous iodinated contrast media ap-pears to have been historically overestimated, although clinically relevant risk persists in vulnerable patients. Proposed mechanisms include renal vasoconstriction, medullary hy-poxia, oxidative stress, mitochondrial dysfunction, tubular epithelial injury, endothelial dysfunction, and inflammatory or apoptotic pathways. Preventive strategies should be in-dividualized, with isotonic saline remaining the main intervention when indicated, whereas routine pharmacologic prophylaxis is not supported by consistent clinically meaningful benefit. Conclusions: Renal safety in contrast-enhanced imaging requires a balanced approach that minimizes avoidable kidney injury in high-risk patients without unnecessarily delaying clinically indicated diagnostic or therapeutic procedures.
- Open Access
- 16 May 2026
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 8 (2) , 23
Artificial Intelligence in Helicobacter Pylori Infection: Diagnostic Applications and Emerging Treatment-Related Predictive Uses—A Systematic Review
Background: Artificial intelligence (AI) has shown growing potential in the diagnosis of H. pylori infection, particularly through automated analysis of endoscopic images. Emerging studies have also explored treatment-related predictive applications, although this evidence remains limited. The aim of this systematic review was to synthesize current evidence on the use of AI in H. pylori infection, with the primary emphasis on diagnosis and secondary consideration of predictive therapeutic applications. Methods: A systematic review was conducted in accordance with PRISMA 2020 guidelines through searches in PubMed, ScienceDirect, EBSCO, and the Cochrane Library, including articles published between 2020 and 2025. Six studies that employed deep learning or machine learning models, primarily convolutional neural networks and predictive classifiers, were selected. Results: Artificial intelligence models showed consistent diagnostic performance, with accuracies ranging from 79.2% to 94%, sensitivities from 62.5% to 96%, and specificities from 79.4% to 93.4%. Convolutional neural network-based systems generally demonstrated diagnostic performance comparable to or better than that of human endoscopists, particularly among less experienced operators. Limited evidence suggests a possible role for artificial intelligence in predicting treatment failure; however, this finding is based on a single included study. Conclusions: Artificial intelligence appears to be a promising complementary tool for the diagnosis of H. pylori infection, particularly in endoscopic imaging. However, evidence regarding treatment-related and resistance-related applications remains limited and indirect, and these potential uses should therefore be considered preliminary.
- 16 May 2026
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 8 (2) , 23
Open AccessArtificial Intelligence in Helicobacter Pylori Infection: Diagnostic Applications and Emerging Treatment-Related Predictive Uses—A Systematic Review
Background: Artificial intelligence (AI) has shown growing potential in the diagnosis of H. pylori infection, particularly through automated analysis of endoscopic images. Emerging studies have also explored treatment-related predictive applications, although this evidence remains limited. The aim of this systematic review was to synthesize current evidence on the use of AI in H. pylori infection, with the primary emphasis on diagnosis and secondary consideration of predictive therapeutic applications. Methods: A systematic review was conducted in accordance with PRISMA 2020 guidelines through searches in PubMed, ScienceDirect, EBSCO, and the Cochrane Library, including articles published between 2020 and 2025. Six studies that employed deep learning or machine learning models, primarily convolutional neural networks and predictive classifiers, were selected. Results: Artificial intelligence models showed consistent diagnostic performance, with accuracies ranging from 79.2% to 94%, sensitivities from 62.5% to 96%, and specificities from 79.4% to 93.4%. Convolutional neural network-based systems generally demonstrated diagnostic performance comparable to or better than that of human endoscopists, particularly among less experienced operators. Limited evidence suggests a possible role for artificial intelligence in predicting treatment failure; however, this finding is based on a single included study. Conclusions: Artificial intelligence appears to be a promising complementary tool for the diagnosis of H. pylori infection, particularly in endoscopic imaging. However, evidence regarding treatment-related and resistance-related applications remains limited and indirect, and these potential uses should therefore be considered preliminary.
- Open Access
- 15 May 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (2) , 34
Correction: Zavaleta-Monestel et al. Sodium Zirconium Cyclosilicate in the Therapeutic Management of Hyperkalemia: A Systematic Review of Efficacy and Safety. Kidney Dial. 2026, 6, 19
- 15 May 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (2) , 34
Open AccessCorrection: Zavaleta-Monestel et al. Sodium Zirconium Cyclosilicate in the Therapeutic Management of Hyperkalemia: A Systematic Review of Efficacy and Safety. Kidney Dial. 2026, 6, 19
- Open Access
- 13 March 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (1) , 19
Sodium Zirconium Cyclosilicate in the Therapeutic Management of Hyperkalemia: A Systematic Review of Efficacy and Safety
Objective: The objective of this study is to evaluate the efficacy and safety of sodium zirconium cyclosilicate in the treatment of hyperkalemia in adult patients based on the available scientific evidence. Methods: A systematic review of randomized controlled trials evaluating SZC in adult patients with hyperkalemia was conducted, including populations with chronic kidney disease and heart failure and patients undergoing hemodialysis. Outcomes assessed included serum potassium reduction, achievement and maintenance of normokalaemia, and adverse events. Results: Seven randomized controlled trials were included. SZC produced a rapid and significant reduction in serum potassium, with reductions of up to 1.28 mmol/L within 48 h and onset of action observed as early as 1–4 h. Across studies, 63–92% of patients achieved normokalaemia within 24–48 h, and maintenance therapy sustained normokalaemia for up to 28 days and longer in selected populations. The most frequently reported adverse events were mild-to-moderate edema and constipation, while hypokalemia was infrequent (<5% in most studies). Conclusions: Sodium zirconium cyclosilicate is an effective and generally well-tolerated option for the management of hyperkalemia, providing rapid potassium reduction and sustained normokalaemia. However, no randomized controlled trial included in this review demonstrated a significant benefit of SZC over comparators in major clinical outcomes—hospitalizations, cardiovascular events, or mortality; the evidence of clinical benefit is therefore absent from the current randomized trial literature.
- 13 March 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (1) , 19
Open AccessSodium Zirconium Cyclosilicate in the Therapeutic Management of Hyperkalemia: A Systematic Review of Efficacy and Safety
Objective: The objective of this study is to evaluate the efficacy and safety of sodium zirconium cyclosilicate in the treatment of hyperkalemia in adult patients based on the available scientific evidence. Methods: A systematic review of randomized controlled trials evaluating SZC in adult patients with hyperkalemia was conducted, including populations with chronic kidney disease and heart failure and patients undergoing hemodialysis. Outcomes assessed included serum potassium reduction, achievement and maintenance of normokalaemia, and adverse events. Results: Seven randomized controlled trials were included. SZC produced a rapid and significant reduction in serum potassium, with reductions of up to 1.28 mmol/L within 48 h and onset of action observed as early as 1–4 h. Across studies, 63–92% of patients achieved normokalaemia within 24–48 h, and maintenance therapy sustained normokalaemia for up to 28 days and longer in selected populations. The most frequently reported adverse events were mild-to-moderate edema and constipation, while hypokalemia was infrequent (<5% in most studies). Conclusions: Sodium zirconium cyclosilicate is an effective and generally well-tolerated option for the management of hyperkalemia, providing rapid potassium reduction and sustained normokalaemia. However, no randomized controlled trial included in this review demonstrated a significant benefit of SZC over comparators in major clinical outcomes—hospitalizations, cardiovascular events, or mortality; the evidence of clinical benefit is therefore absent from the current randomized trial literature.